statistiche ricercatore

Continente	#
NA - Nord America	484
AS - Asia	406
EU - Europa	326
SA - Sud America	101
AF - Africa	15
Continente sconosciuto - Info sul continente non disponibili	1
Totale	1.333

Nazione	#
US - Stati Uniti d'America	462
SG - Singapore	179
DE - Germania	100
CN - Cina	93
BR - Brasile	85
VN - Vietnam	46
IT - Italia	45
SE - Svezia	44
FR - Francia	34
GB - Regno Unito	20
IE - Irlanda	19
IN - India	19
UA - Ucraina	19
CA - Canada	13
HK - Hong Kong	13
JP - Giappone	13
FI - Finlandia	8
ID - Indonesia	8
BD - Bangladesh	7
NL - Olanda	6
PL - Polonia	6
TR - Turchia	6
AR - Argentina	5
ES - Italia	5
IQ - Iraq	5
PY - Paraguay	5
RU - Federazione Russa	5
EC - Ecuador	4
MX - Messico	4
ZA - Sudafrica	4
AT - Austria	3
BE - Belgio	3
IR - Iran	3
KR - Corea	3
AE - Emirati Arabi Uniti	2
AL - Albania	2
CH - Svizzera	2
EG - Egitto	2
KE - Kenya	2
RO - Romania	2
SA - Arabia Saudita	2
SN - Senegal	2
A2 - ???statistics.table.value.countryCode.A2???	1
CI - Costa d'Avorio	1
CO - Colombia	1
CR - Costa Rica	1
HN - Honduras	1
JM - Giamaica	1
LA - Repubblica Popolare Democratica del Laos	1
LB - Libano	1
LI - Liechtenstein	1
LK - Sri Lanka	1
LU - Lussemburgo	1
MA - Marocco	1
MY - Malesia	1
NE - Niger	1
NO - Norvegia	1
NP - Nepal	1
PA - Panama	1
PH - Filippine	1
PK - Pakistan	1
SC - Seychelles	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
VE - Venezuela	1
Totale	1.333

Nome	#
Surgery of children with frontal lobe lesional epilepsy: neuropsychological study	178
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience	152
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy	150
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction	136
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study	132
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study	131
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016	130
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls	119
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial	111
An observational study of functional abilities in infants, children, and adults with type 1 SMA	106
Totale	1.345

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	10	0	0	0	0	0	0	0	0	0	0	7	3
2021/2022	58	2	4	1	2	5	4	1	12	2	5	9	11
2022/2023	161	14	17	15	25	9	25	12	16	22	0	4	2
2023/2024	73	2	25	2	6	1	18	3	1	1	3	7	4
2024/2025	204	4	4	12	5	13	8	5	10	31	16	38	58
2025/2026	652	95	37	50	104	123	32	90	34	42	45	0	0
Totale													1.345

IRIS UniCatt